Immune checkpoint inhibitors

Immunology-based therapy is rapidly developing into an effective treatment option for a surprising range of cancers. We have learned over the last decade that powerful immunologic effector cells may be blocked by inhibitory regulatory pathways controlled by specific molecules often called "immune checkpoints." The development of a new therapeutic class of drugs that inhibit these inhibitory pathways has recently emerged as a potent strategy in oncology. Three sets of agents have emerged in clinical trials exploiting this strategy. These agents are antibody-based therapies targeting cytotoxic T-lymphocyte antigen 4 (CTLA4), programmed cell death 1 (PD-1), and programmed cell death ligand 1 (PD-L1). These inhibitors of immune inhibition have demonstrated extensive activity as single agents and in combinations. Clinical responses have been seen in melanoma, renal cell carcinoma, small cell lung cancer, and several other tumor types.

  • Drugs
  • Recognision of immune cells
  • Attacking mechanisms
  • Adverse effects of these drugs
  • Considerations in Using/Prescribing
  • PD-1 or PD-L1 Targetors/Targets
  • Targetting CTLA-4

Related Conference of Immune checkpoint inhibitors

November 06-07, 2017

2nd International Conference on Autoimmunity

Frankfurt, Germany
November 08-09, 2017

3rd Antibodies and Bio Therapeutics Congress & B2B

Las Vegas, Nevada, USA
November 13-14, 2017

5th International Conference on HIV/AIDS, STDs and STIs

Las Vegas, Nevada, USA
Dec 14-15, 2017

World Immunology Congress

Dubai, UAE
May 28-29, 2018

World Congress on Allergy and Immunotherapy

Osaka, Japan

9th European Immunology Conference

June 14-16, 2018 Rome, Italy
July 12-13, 2018

5th International Conference on Parasitology

Paris, France

Immune checkpoint inhibitors Conference Speakers

Recommended Sessions

Related Journals

Are you interested in